Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Insmed (Nasdaq: INSM) granted inducement awards to 85 new employees under its 2025 Inducement Plan on Feb 27, 2026. The grants comprised 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share.

RSUs vest over four years (25% each year). Options have a 10-year term and four-year vesting: 25% at first anniversary, then 12.5% every six months thereafter, subject to continued service.

News Market Reaction – INSM

-4.21%

1 alert

-4.21% News Effect

On the day this news was published, INSM declined 4.21%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

New employees: 85 employees Restricted stock units: 68,947 RSUs Stock options granted: 4,710 options +3 more

6 metrics

New employees 85 employees Recipients of inducement equity awards

Restricted stock units 68,947 RSUs Inducement grants under 2025 Inducement Plan

Stock options granted 4,710 options Options to purchase Insmed common stock

Option exercise price $149.33 per share Closing price on Nasdaq Global Select Market at grant date

RSU vesting period 4 years 25% vests on each annual anniversary after grant reference date

Option term 10 years Option contractual life from grant date

Market Reality Check

Price: $139.50 Vol: Volume 1,729,214 is at 0....

normal vol

$139.50 Last Close

Volume Volume 1,729,214 is at 0.71x the 20-day average, indicating lighter-than-normal trading. normal

Technical Shares at $149.88, trading above the 200-day MA of $143.38, suggesting an established uptrend pre-announcement.

Peers on Argus

INSM gained 1.96% pre-news while peers showed mixed moves: BNTX, ONC, REGN, GMAB...

INSM gained 1.96% pre-news while peers showed mixed moves: BNTX, ONC, REGN, GMAB up and ARGX down, pointing to stock-specific dynamics rather than a unified biotech move.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Earnings and outlook	Positive	+6.5%	Strong 2025 revenue, cash position, and upbeat 2026 product guidance.
Feb 13	Investor conferences	Neutral	+1.8%	Announcement of March 2026 investor conference presentations and webcasts.
Feb 05	Earnings call notice	Neutral	-0.9%	Scheduling of Q4 and full-year 2025 results call and webcast details.
Jan 28	Scientific conference data	Positive	-4.2%	Multiple TPIP abstracts and Phase 2b/3 data presentations at PVRI 2026.
Jan 09	Business update	Positive	+3.4%	Preliminary 2025 revenues, BRINSUPRI EU approval, and key 2026 readout plans.

Pattern Detected

Recent news with strong fundamentals or strategic updates has usually seen positive price reactions, with one notable divergence on a scientific conference update.

Recent Company History

Over recent months, Insmed has reported strong 2025 revenue of $606.4M and guided to at least $1B in 2026 BRINSUPRI revenue, with ARIKAYCE 2026 guidance of $450M–$470M (Feb 19 earnings and 8-K). Earlier, at the Jan 9 J.P. Morgan update, it highlighted 67% revenue growth and positive late-stage data, which also drew a positive reaction. Conference-related news, including TPIP abstracts at PVRI on Jan 28, saw a negative move despite seemingly constructive scientific content, showing occasional divergence on R&D-heavy announcements.

Market Pulse Summary

This announcement details equity inducement awards to 85 new employees, totaling 68,947 restricted s...

Analysis

This announcement details equity inducement awards to 85 new employees, totaling 68,947 restricted stock units and options on 4,710 shares at an exercise price of $149.33. The grants vest over four years, aligning employee incentives with longer-term shareholder outcomes. Placed against recent strong revenue growth and active late-stage pipeline news, this filing underscores ongoing hiring and retention efforts. Investors may watch overall share-based compensation trends alongside upcoming clinical and commercial milestones.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"the employees received 68,947 restricted stock units and options to purchase"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. Not financial advice.

BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, on February 27, 2026, the employees received 68,947 restricted stock units and options to purchase an aggregate 4,710 shares of Insmed common stock at an exercise price of $149.33 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The restricted stock units have a four-year vesting schedule, with 25% of the shares underlying each restricted stock unit grant vesting on each anniversary of the first day of the month immediately following the grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the first day of the month immediately following the grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary thereof, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:

Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302704468.html

SOURCE Insmed Incorporated

FAQ

How many employees received inducement awards from Insmed (INSM) on Feb 27, 2026?

Eighty-five new employees received inducement awards. According to Insmed, the grants were made under its 2025 Inducement Plan as material inducements for new hires.

What equity was granted to new hires in Insmed (INSM) inducement awards on Feb 27, 2026?

Insmed granted 68,947 restricted stock units and options to purchase 4,710 shares. According to Insmed, the options carry an exercise price of $149.33 per share.

What is the vesting schedule for the restricted stock units in Insmed's (INSM) inducement grants?

The RSUs vest over four years with 25% vesting each anniversary. According to Insmed, vesting is subject to the employee's continued service on each applicable vesting date.

What are the terms and vesting details for the options in Insmed's (INSM) inducement awards?

Options have a 10-year term and a four-year vesting schedule with 25% vesting at the first anniversary. According to Insmed, remaining option shares vest 12.5% every six months through year four.

At what exercise price were Insmed's (INSM) inducement option grants issued on Feb 27, 2026?

Options were issued at an exercise price of $149.33 per share, equal to the Nasdaq closing price on the grant date. According to Insmed, that price reflects the market close on Feb 27, 2026.